Author: ["Joseph E. Ebinger","Justyna Fert-Bober","Ignat Printsev","Min Wu","Nancy Sun","John C. Prostko","Edwin C. Frias","James L. Stewart","Jennifer E. Van Eyk","Jonathan G. Braun","Susan Cheng","Kimia Sobhani"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose. Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals.Cite this article
Ebinger, J.E., Fert-Bober, J., Printsev, I. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med (2021). https://doi.org/10.1038/s41591-021-01325-6 